Skip to main content
Premium Trial:

Request an Annual Quote

ESA Biosciences Gets $500K From NIH to Develop Metabolomics Platform

NEW YORK, March 24 (GenomeWeb News) - The US National Institutes of Heath has awarded Chelmsford, Mass.-based ESA Biosciences $538,619 to support the development of technologies to study metabolomics, GenomeWeb News has learned.


The grant, named "Integrating Lcec/Lcm in a Single Metabolomics Platform," was awarded to the company as part of the NIH Roadmap for Medical Research initiative, the company said in a statement.


"We will work toward developing a rugged platform that will incorporate both MS and EC detection in parallel, communicating with each other, to produce results that individually would not be possible," Ian Acworth, ESA vice president of HPLC products and services, said in the statement. The research will also incorporate ESA's new, breakthrough HPLC detection technology, the Corona Charged Aerosol Detector, the company added.


The company will conduct its research in collaboration with Oak Ridge National Laboratory, Applied Biosystems/MDS SCIEX, Millennium Pharmaceuticals, Cornell University Medical School, MassachusettsCollege of Pharmacy, BostonUniversityMedicalSchool, and Burke Medical Research Institute, ESA said.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.